Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | 222 | ACCESS Newswire | In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire... ► Artikel lesen | |
16.05. | CNS Pharmaceuticals reports Q1 results | 4 | Seeking Alpha | ||
16.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | 311 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme... ► Artikel lesen | |
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
15.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.05. | CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement | 1 | RTTNews | ||
13.05. | CNS Pharmaceuticals sets terms for $5 million stock offering | 3 | Investing.com | ||
13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 632 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
13.05. | Pre-market Movers: Lobo EV Technologies, CNS Pharmaceuticals, Landsea Homes, Inno Holdings, Lichen International | 494 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.25 A.M. ET).In the Green Lobo EV Technologies Ltd. (LOBO) is up over 160%... ► Artikel lesen | |
13.05. | CNS Pharmaceuticals erhält Orphan-Drug-Status für Krebsmedikament | 7 | Investing.com Deutsch | ||
13.05. | CNS Pharmaceuticals secures orphan drug status for cancer drug | 2 | Investing.com | ||
13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | 550 | ACCESS Newswire | Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Management... ► Artikel lesen | |
12.05. | CNS Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
14.04. | CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants | 1 | Seeking Alpha | ||
14.04. | CNS Pharmaceuticals, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
09.04. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
01.04. | CNS Pharmaceuticals reports FY results | 2 | Seeking Alpha | ||
01.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Full Year 2024 Financial Results | 290 | ACCESS Newswire | Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy... ► Artikel lesen | |
31.03. | CNS Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
31.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
25.03. | XFRA BE5: WIEDERAUFNAHME/RESUMPTION | 301 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,798 | -0,58 % | CureVac-Aktie +32%: BioNTech kauft den deutschen Rivalen! | Buyout-Hammer zur Mittagszeit: Das Mainzer Biotech-Unternehmen BioNTech will den deutschen Rivalen CureVac übernehmen. Eine entsprechende Transaktion wurde vor Kurzem angekündigt. Während die CureVac-Aktie... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,086 | 0,00 % | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,580 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 1,025 | +4,24 % | Ocugen To Present at BIO International Convention 2025 | ||
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,000 | +3,09 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,520 | +3,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,571 | -7,01 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,074 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS46122W2044 Inuvo Inc. 10.06.2025 US46122W3034 Inuvo Inc. 11.06.2025 Tausch 10:1CA1208311029 Burcon Nutrascience... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,332 | -7,26 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 0,061 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA74061L1040 NexMetals Mining Corp. 12.06.2025 CA65346E1051 NexMetals Mining Corp. 13.06.2025 Tausch 1:1US68237Q1040 Onconetix... ► Artikel lesen | |
IMMUNIC | 0,689 | -0,86 % | EQS-News: Immunic AG: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,097 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |